Partnership Aimed at Delivering Psychedelic Capsule for Dosing Study in Human Clinical Trial VANCOUVER, BC, May 11, 2021 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, and Optimi Health Corp. (CSE: OPTI) (OTC: OPTHF) (FRA: 8BN), developers of a vertically…


Previous articlePT243 – Dr. Fernando Espi Forcen and Dr. Franklin King of MGH’s Center for the Neuroscience of Psychedelics
Next articleHenrik Dahl’s Review of Pickard’s ‘The Rose of Paracelsus: On Secrets and Sacraments’